AzTrials
AzTrials

Chronic Kidney DiseaseUToPaed_2NCT02620969

Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Kinetic Analysis

An observational study of Chronic Kidney Disease, run by University Hospital, Ghent at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Children with chronic kidney disease (CKD) suffer from one of the most devastating diseases in childhood resulting in a lifelong need for health care, and a 3 times decreased life expectancy. Read more about this study

Who is it for?
Ages Up to 18 years
Conditions the study is for
Chronic Kidney Disease
What is being tested?
Blood and dialysate sampling
How many people
20 participants
Where
1 siteBelgium
Study dates
Oct 2015to Oct 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: CKD patients treated with haemodialysis

Subject Inclusion Criteria:

  • Provide signed and dated informed consent form.
  • Willing to comply with all study procedures and be available for the duration of the study
  • Male or female, aged ≤ 18 years
  • Diagnosed with chronic kidney disease stage 5D and treated with haemodialysis

Subject Exclusion Criteria:

  • N.A.

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Ghent University Hospital

    Ghent

Other trials in Belgium

About this study

Official title: Part 2 of: 'Conceptualisation and Validation of a Paradigm Based on Uraemic Toxins for Management of Chronic Kidney Disease in Paediatric Patients (UToPaed)'

Children with chronic kidney disease (CKD) suffer from one of the most devastating diseases in childhood resulting in a lifelong need for health care, and a 3 times decreased life expectancy. In addition, they have important comorbidities that negatively impact on their quality of life and integration in society, jeopardizing their future even after a potential transplantation. Retention of uraemic toxins is accepted to play a major role in the pathogenesis of the comorbid conditions, but studies in children are lacking. Furthermore, there are currently no good tools to evaluate severity and monitor adequacy of treatment, resulting in suboptimal management.

The overall scientific objective of this four years UToPaed IWT-TBM project is to provide the clinician with new diagnostic and therapeutic tools for the management of children with CKD, based on the improved understanding of uraemic toxicity.

Read more

In the first part of UToPaed, the investigators will associate concentrations of a wide variety of uraemic toxins with different comorbidities in CKD children. In this second part, a kinetic analysis will be performed to unravel the distribution and transport of the different studied uraemic toxins in the body of the patient. The toxins of which concentrations are best correlated with comorbidities during the progress of CKD (UToPaed - part 1: observational study) and have representative kinetics will be selected as markers. These markers will be, together with the comorbidities, further tracked after interventions, i.e. starting on dialysis, transplantation, changes in dialysis strategy (UToPaed - part 3 - intervention study) in order to validate the different kinetic models.

From the validated kinetic models (UToPaed - part 2 and 3), an open access user-friendly prediction simulator (PAEDSIM) based on patient characteristics and marker concentrations will be developed to optimise and individualise the dialysis therapy.

By providing clinicians with more advanced and appropriate tools to improve management of all children with CKD, i.e. better assessment of the degree of renal dysfunction, better determination of the ideal time to start renal replacement therapy, and more accurate monitoring of dialysis adequacy, the investigators aim to improve neurocognitive and psychosocial functioning (short term), growth, maturation into puberty, and social integration (median term) and survival (long term).

Read the detailed description

This is an observational multicenter study in 20 children (≤ 18 years) with chronic kidney disease (CKD) stage 5D treated with haemodialysis.

Distribution and transport of uraemic toxins inside the body is derived from a cross-sectional study. During a midweek haemodialysis session, blood is sampled from the dialyser inlet line at different time points (e.g. at 0, 15, 30, 60, 120, 240min) during the session to obtain the evolution of intradialytic concentrations as is needed for the kinetic analysis. To calculate dialyser clearance, blood is sampled simultaneously at the dialyser inlet and outlet in the first part of the session (e.g. at 30min). Total solute removal is measured by partial dialysate collection during the entire dialysis duration, using a validated sampling system. For each uraemic toxin under study, a kinetic model is calibrated simulating distribution and mass transport inside the patient's body. The body is characterised by a total distribution volume V (per toxin), consisting of one or more distinct compartments. In e.g. a 2-compartment model, one can distinguish a plasmatic or peripheral compartment, which is directly cleared by haemodialysis (i.e. dialyser clearance) or by renal or extrarenal clearances, and extraplasmatic compartment(s). Each compartment is assumed to be characterised by a homogeneous uraemic toxin concentration with variable inputs and outputs. The solute transport between two compartments is considered to be driven by concentration gradients (diffusion), and/or pressure gradients (convection) and is characterised by an intercompartment clearance.

Presuming that removal and generation are in equilibrium in stable HD patients, solute generation rate in the interdialytic period is assumed equal to the total solute removal during the dialysis session. The patient-specific ultrafiltration rate is taken into account to change total distribution volume over time.

The time variation of the compartment concentration is, for a particular toxin, determined by solving the mass balance equation for each compartment. The kinetic model iteratively solves these equations for the complete dialysis session time. Herewith, plasmatic volume, total distribution volume, as well as intercompartment clearance are calculated from fitting the solution to the measured patient's plasma concentrations. Such kinetic analyses result in the knowledge of all kinetic parameters for each studied toxin.

These calibrated kinetic models for paediatrics are further used to simulate different dialysis strategies and, with it, look for the most optimal one, with the experience the investigators have from kinetic studies in adults. Herewith, per solute, inter- and intradialytic evolutions in concentration are calculated according to the mass balance equations per compartment using the derived kinetic parameters. In the interdialytic period, dialyser clearance is kept at zero, while solute generation is maintained constant, and the interdialytic volume gain is set equal to the intradialytic applied ultrafiltration rate. Starting from the intra- and interdialytic concentrations in steady state with a 3x4 hours dialysis schedule, intra- and interdialytic concentrations are calculated after mathematically altering several key characteristics of the dialysis regime. This is done for the individual paediatric patient data as well as for the average paediatric patient within its age category with data emanating out of our primary kinetic analysis. Possible strategies are: longer and/or more frequent dialysis with or without adapting blood and/or dialysate flow rates, increasing convection, haemodiafiltration (pre, post, or mixed dilution), or a combination accounting for different parameters. For each strategy, consecutive sessions are simulated until a new steady state of predialysis solute concentrations is reached (deviation between 2 consecutive sessions <1%), paralleling the real in vivo effect of altering dialysis strategy.

The different strategies are evaluated mathematically by comparing the calculated total solute removal during the first week with the new strategy, and the steady state time averaged as well as predialysis concentrations in the plasmatic volume.

The calibrated kinetic modelling parameters and the results of the different dialysis strategies are compared for the different studied uraemic toxins. Accounting for the correlations with comorbidities (UToPaed-part 1), one (or more) uraemic toxin marker(s) are chosen.

The kinetic models are further validated by quantifying uraemic toxin marker concentrations and comorbidities in individual patients after switching to different strategies as well as to the individualised optimal dialysis strategy based on the model (UToPaed- part 3).

Being tested
Blood and dialysate sampling
Keywords
Paediatrics, Haemodialysis, Kinetics
Medical subject headings
Renal Insufficiency, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood and dialysate samplingOther

    Blood and dialysate sampling

Study groups in NCT02620969
Study groupRoleWhat they receive
Patients on haemodialysisDuring a midweek session of a patient on haemodialysis, blood and dialysate sampling is performed at different time points.
Receives: Other: Blood and dialysate sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Calibration of kinetic models per studied uraemic toxin

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Dec 2015 (estimated)
  2. Study startOct 2015
  3. Primary completionOct 2018
  4. Study completionOct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02620969
Sponsor's protocol ID
UGent_UToPaed_2
Acronym
UToPaed_2
Status last verified
Feb 2019
First submitted
1 Dec 2015
Last updated
15 Feb 2019
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Kidney Disease, run by University Hospital, Ghent at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Calibration of kinetic models per studied uraemic toxin (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in